Craig M Kessler

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi request reprint Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature
    E Asatiani
    Hemophilia and Thrombophilia Comprehensive Care Center, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
    Haemophilia 13:685-96. 2007
  2. doi request reprint Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates
    Craig M Kessler
    Division of Coagulation, Georgetown University Medical Center, Washington, District of Columbia 20007, USA
    Blood Coagul Fibrinolysis 23:262-7. 2012
  3. pmc Consensus recommendations for the diagnosis and treatment of acquired hemophilia A
    Peter Collins
    Arthur Bloom Hemophilia centre, School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, CF14 4XN, UK
    BMC Res Notes 3:161. 2010
  4. ncbi request reprint Update on liver disease in hemophilia patients
    Craig M Kessler
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Semin Hematol 43:S13-7. 2006
  5. ncbi request reprint Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?
    C M Kessler
    Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC 20057, USA
    J Thromb Haemost 4:963-6. 2006
  6. ncbi request reprint New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate
    C M Kessler
    Division of Hematology and Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
    Curr Opin Hematol 7:408-13. 2000
  7. doi request reprint Diagnosis and treatment of von Willebrand disease: new perspectives and nuances
    C M Kessler
    Lombardi Comprehensive Cancer Center, Division of Haematology Oncology, Georgetown University Medical Center, Washington, DC, USA
    Haemophilia 13:3-14. 2007
  8. doi request reprint Recent developments in topical thrombins
    Craig M Kessler
    Department of Laboratory Medicine, Georgetown University, Washington, DC, USA
    Thromb Haemost 102:15-24. 2009
  9. doi request reprint The link between cancer and venous thromboembolism: a review
    Craig M Kessler
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Am J Clin Oncol 32:S3-7. 2009
  10. doi request reprint The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study
    Craig M Kessler
    Hemophilia and Thrombophilia Comprehensive Treatment Center, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Thromb Haemost 106:279-88. 2011

Detail Information

Publications28

  1. ncbi request reprint Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature
    E Asatiani
    Hemophilia and Thrombophilia Comprehensive Care Center, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
    Haemophilia 13:685-96. 2007
    ..Successful therapy required an individualized approach, employing multiple replacement strategies, based on the laboratory definition of the specific additional coagulation defect...
  2. doi request reprint Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates
    Craig M Kessler
    Division of Coagulation, Georgetown University Medical Center, Washington, District of Columbia 20007, USA
    Blood Coagul Fibrinolysis 23:262-7. 2012
    ..This new approach may be a more suitable alternative for hemostatic assessment of coagulation products in VWD patients than the currently used subjective methods...
  3. pmc Consensus recommendations for the diagnosis and treatment of acquired hemophilia A
    Peter Collins
    Arthur Bloom Hemophilia centre, School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, CF14 4XN, UK
    BMC Res Notes 3:161. 2010
    ..AHA usually presents to clinicians without prior experience of the disease, therefore diagnosis is frequently delayed and bleeds under treated...
  4. ncbi request reprint Update on liver disease in hemophilia patients
    Craig M Kessler
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Semin Hematol 43:S13-7. 2006
    ....
  5. ncbi request reprint Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?
    C M Kessler
    Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC 20057, USA
    J Thromb Haemost 4:963-6. 2006
  6. ncbi request reprint New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate
    C M Kessler
    Division of Hematology and Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
    Curr Opin Hematol 7:408-13. 2000
    ..This review will discuss this new medication and place into the context of coagulation inhibitor therapy...
  7. doi request reprint Diagnosis and treatment of von Willebrand disease: new perspectives and nuances
    C M Kessler
    Lombardi Comprehensive Cancer Center, Division of Haematology Oncology, Georgetown University Medical Center, Washington, DC, USA
    Haemophilia 13:3-14. 2007
  8. doi request reprint Recent developments in topical thrombins
    Craig M Kessler
    Department of Laboratory Medicine, Georgetown University, Washington, DC, USA
    Thromb Haemost 102:15-24. 2009
    ..Well-designed and adequately powered clinical trials should be conducted to indicate whether human thrombin products would improve the risk-benefit and cost-benefit profiles for surgeries complicated by excessive bleeding...
  9. doi request reprint The link between cancer and venous thromboembolism: a review
    Craig M Kessler
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Am J Clin Oncol 32:S3-7. 2009
    ..VTE continues to pose a substantial risk to patients with cancer because of a variety of tumor-, host-, and therapy-related factors...
  10. doi request reprint The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study
    Craig M Kessler
    Hemophilia and Thrombophilia Comprehensive Treatment Center, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Thromb Haemost 106:279-88. 2011
    ..The PK profile of Wilate, combined with the 1:1 VWF/FVIII ratio, theoretically should facilitate dosing and laboratory monitoring of VWF replacement to prevent bleeding in individuals with VWD...
  11. ncbi request reprint B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study
    C M Kessler
    Georgetown University Medical Center, Washington, DC 20007 2197, USA
    Haemophilia 11:84-91. 2005
    ..BDDrFVIII (ReFacto) has been developed with the additional benefit of being formulated without human albumin...
  12. ncbi request reprint Antidotes to haemorrhage: recombinant factor VIIa
    Craig M Kessler
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Best Pract Res Clin Haematol 17:183-97. 2004
    ..Evidence-based data are necessary to establish the cost-benefit and risk-benefit profiles of rFVIIa, and to establish it as a standard treatment for bleeding...
  13. ncbi request reprint Current and future challenges of antithrombotic agents and anticoagulants: Strategies for reversal of hemorrhagic complications
    Craig M Kessler
    Department of Medicine, Georgetown University of Medicine, Washington, DC 20007, USA
    Semin Hematol 41:44-50. 2004
    ....
  14. ncbi request reprint Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate
    Kashif Firozvi
    Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Am J Hematol 81:582-9. 2006
    ....
  15. ncbi request reprint Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate
    Ruby Anne E Deveras
    Division of Hematology and Oncology, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2197, USA
    Ann Intern Med 137:884-8. 2002
    ..Safe and rapid reversal of excessive anticoagulation is occasionally needed to treat or avoid hemorrhagic complications...
  16. ncbi request reprint Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use
    Slawomir Sobieszczyk
    Division of Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Acta Obstet Gynecol Scand 85:1239-47. 2006
    ..Anecdotal experiences in the empirical use of this agent are described and dosing regimens, effects on bleeding, and safety data are presented...
  17. doi request reprint The pivotal role of thrombin in cancer biology and tumorigenesis
    Kristen M Snyder
    Divisions of Pediatric and Adult Hematology Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Semin Thromb Hemost 34:734-41. 2008
    ....
  18. ncbi request reprint Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement
    Ekatherine Asatiani
    Georgetown University Hospital, Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Am J Hematol 77:144-6. 2004
    ..0007). Prevalence of monoclonal gammopathy is higher than previously recognized and indicates advanced disease. However, the prognostic significance of the presence of monoclonal gammopathy in this population is unknown...
  19. pmc D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism
    B H Mavromatis
    Division of Hematology Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Pathol 54:664-8. 2001
    ..D-dimer measurements are very sensitive in excluding a diagnosis of pulmonary embolism in the setting of normal values, a low clinical suspicion, and non-diagnostic lung scans. Several assays have been developed and are reviewed...
  20. ncbi request reprint Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders
    Craig M Kessler
    Vincent T Lombardi Cancer Center, MedStar Georgetown Medical Center, Washington, DC 20007 2197, USA
    Semin Hematol 41:10-4. 2004
    ..The role of leukocytosis in bleeding or hemorrhage in this population remains to be elucidated...
  21. ncbi request reprint Advances in the treatment of hemophilia
    Craig M Kessler
    Department of Medicine and Pathology, Division of Hematology Oncology, Clinical Coagulation Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Clin Adv Hematol Oncol 6:184-7. 2008
  22. ncbi request reprint The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A
    J M Lusher
    Division of Hematology and Oncology, Children s Hospital of Michigan, Detroit, MI 48201, USA
    Haemophilia 9:38-49. 2003
    ..B-domain-deleted recombinant factor VIII (BDDrFVIII) was developed when the B-domain was found to be redundant for maintaining haemostasis. This allows formulation of the final product without albumin added as a stabilizer...
  23. doi request reprint Microvascular free flap failure caused by unrecognized hypercoagulability
    Steven P Davison
    Department of Plastic Surgery, Division of Coagulation, Georgetown University Hospital, Washington, DC, USA
    Plast Reconstr Surg 124:490-5. 2009
    ..However, despite technical and patient-selection advances, some components of free flap failure might be attributable to undiagnosed patient factors...
  24. ncbi request reprint Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
    N Engl J Med 348:1425-34. 2003
    ..0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio...
  25. ncbi request reprint End-stage liver disease in persons with hemophilia and transfusion-associated infections
    James J Goedert
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
    Blood 100:1584-9. 2002
    ..04-fold (95% CI, 1.03-1.06) per year of age. Thus, HIV is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4(+) lymphocytes, or older age...
  26. ncbi request reprint Antithrombin, heparin, and heparan sulfate
    Steven M Opal
    Infectious Disease Division, Brown Medical School, Providence, RI 02860, USA
    Crit Care Med 30:S325-31. 2002
    ..The interaction between antithrombin and specific polysulfated, acidic oligosaccharide moieties found on heparin and related proteoglycan molecules within the circulation and on endothelial surfaces will also be examined...
  27. ncbi request reprint Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
    Steven R Deitcher
    Section of Hematology and Coagulation Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Clin Appl Thromb Hemost 12:389-96. 2006
    ..Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy...
  28. ncbi request reprint Fibrinolytic markers and vasodilatory capacity following acute exercise among men of differing training status
    Tracy Baynard
    Department of Exercise Science, Syracuse University, Syracuse, NY, USA
    Eur J Appl Physiol 101:595-602. 2007
    ..These findings demonstrate that in healthy young men different physical activity patterns do not appear to impact the exercise-induced changes in fibrinolysis or vasodilatory capacity...